Usana Health Sciences Inc key statistics and ratios

In fiscal 2025, Usana Health Sciences Inc had return on equity of 2.0%, an operating margin of 4.0%, debt equal to 2.6% of equity and a current ratio of 2.24. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Usana Health Sciences Inc: financial ratios, annual
Fiscal year	2009Jan 2010	2010Jan 2011	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Jan 2015	2015Jan 2016	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Jan 2021	2021Jan 2022	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Jan 2026	LTMJul 2026
Gross margin	79.4%	81.6%	82.5%	82.1%	82.3%	82.2%	82.6%	82.1%	82.9%	83.1%	82.3%	81.6%	81.6%	80.6%	80.8%	81.1%	78.3%	77.4%
Operating margin	11.6%	13.2%	13.3%	15.1%	16.3%	14.7%	15.4%	13.8%	12.7%	15.8%	13.8%	15.6%	14.3%	10.8%	10.1%	7.8%	4.0%	−0.1%
Net margin	7.7%	8.8%	8.7%	10.2%	11.0%	9.7%	10.3%	9.9%	6.0%	10.6%	9.5%	11.0%	9.8%	6.9%	6.9%	4.9%	1.2%	−2.4%
Free-cash-flow margin	6.5%	12.0%	10.2%	13.0%	12.6%	10.7%	9.6%	10.4%	10.6%	11.8%	10.4%	12.8%	9.1%	9.4%	6.1%	6.0%	0.9%	1.7%
Return on equity	45.1%	41.3%	31.6%	37.0%	35.4%	31.2%	37.1%	33.0%	18.2%	33.5%	27.1%	31.4%	27.8%	16.7%	13.7%	8.2%	2.0%	−4.2%
Return on assets	—	21.1%	22.0%	26.0%	24.9%	21.3%	24.5%	22.4%	12.6%	23.5%	18.8%	21.5%	19.1%	11.8%	10.4%	6.1%	1.4%	−3.1%
Asset turnover	—	2.39	2.52	2.53	2.26	2.20	2.37	2.25	2.12	2.22	1.98	1.96	1.95	1.70	1.50	1.24	1.24	1.26
Current ratio	—	1.38	1.78	1.87	2.39	1.76	1.86	2.01	2.41	2.64	2.42	2.53	2.27	2.67	3.52	2.00	2.24	2.66
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	4.3%	2.6%	0.0%
Interest cover (operating income ÷ interest)	83.4x	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	44.5x	n/m
Effective tax rate	34.2%	33.7%	34.5%	32.5%	32.2%	33.7%	33.6%	27.8%	53.6%	34.1%	33.2%	29.9%	31.7%	36.2%	37.7%	44.9%	72.4%	—
R&D as % of revenue	—	0.7%	0.7%	0.7%	0.7%	0.6%	0.7%	0.9%	0.9%	0.9%	1.0%	0.9%	0.9%	1.2%	1.2%	1.4%	1.2%	—
SG&A as % of revenue	22.9%	23.3%	23.6%	23.8%	23.1%	23.3%	22.8%	23.3%	25.3%	23.1%	25.2%	23.0%	23.5%	26.3%	27.9%	30.8%	36.5%	36.6%
Capital spending as % of revenue	0.9%	0.8%	1.8%	1.3%	1.1%	2.6%	2.6%	3.3%	1.3%	1.0%	1.6%	1.3%	1.1%	1.0%	1.6%	1.2%	1.5%	1.3%
Free cash flow ÷ net income	84.5%	135.6%	117.2%	127.0%	115.0%	110.6%	92.7%	104.2%	176.8%	111.5%	109.6%	116.6%	93.1%	134.8%	88.0%	121.1%	79.2%	—
Dividends and buybacks ÷ free cash flow	5.8%	27.5%	56.3%	80.9%	19.9%	163.8%	69.7%	62.0%	45.2%	74.9%	136.2%	39.2%	164.0%	27.1%	20.7%	18.5%	322.6%	0.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Usana Health Sciences Inc: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Jan 2026	2026 Q1Apr 2026	2026 Q2Jul 2026
Gross margin	80.4%	82.0%	79.0%	78.7%	77.2%	78.2%	76.2%	78.3%
Operating margin	7.8%	3.8%	6.3%	7.1%	0.6%	1.7%	5.5%	−9.0%
Net margin	5.3%	2.1%	3.8%	4.1%	−3.1%	−0.8%	3.0%	−9.6%
Free-cash-flow margin	13.6%	1.9%	5.1%	3.0%	−2.4%	−2.7%	2.8%	9.0%
Current ratio	3.93	2.00	2.05	2.15	2.23	2.24	2.51	2.66
SG&A as % of revenue	30.6%	34.3%	36.6%	34.7%	40.2%	34.5%	35.3%	36.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · July 4, 2026

What it owns · $703m

Short-term assets $281mLonger-term assets $422m

What it owes, and who funded it · $659m

Short-term liabilities $106mLonger-term liabilities $27mShareholders' equity $526m

Short-term assets cover short-term liabilities $281m of assets due within a year against $106m of liabilities due within a year.
Short-term assets cover long-term liabilities $281m short-term assets against $27m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$1m against $412,000 of interest.

From Usana Health Sciences Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

72 /100

Strong moat

How hard Usana Health Sciences's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 20 / 20

Net income has been a median 15.0% of total assets over 10 years.
Pricing power 20 / 20

Gross margin has been a median 81.4%, moving by 1.6 percentage points (standard deviation) across 10 years.
Durability 3 / 20

Operating margin has been a median 12.8%; its worst year was -0.1%.
Cash conversion 14 / 20

Free cash flow was positive in 10 of 10 years, at a median 8.8% of revenue.
Discipline 20 / 20

The diluted share count fell 12.3% over five years; stock-based pay has been a median 1.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (78 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ODD vs USNA NUS vs USNA IPAR vs USNA NATR vs USNA

More: Personal Care Products stocks compared, Consumer Staples sector, rankings of US companies

Figures from Usana Health Sciences Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Usana Health Sciences Inc.